VRDN Q3 2019 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$695,000-26.4% YoY

Gross Profit

-$8M-1198.8% margin

Operating Income

-$11M-1615.8% margin

Net Income

-$11M-1615.8% margin

EPS (Diluted)

$-5.42

QoQ Revenue Growth

-72.4%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$874,000

Balance Sheet

Total Assets

$39M

Total Liabilities

$16M

Stockholders' Equity

$23M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$695,000	$944,000	-26.4%
Gross Profit	-$8M	-$6M	-29.1%
Operating Income	-$11M	-$9M	-22.7%
Net Income	-$11M	-$9M	-24.6%

Revenue Segments

Collaboration Revenue

$625,00047%

Reimbursement Revenue

$625,00047%

Grant

$70,0005%